0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Neutropenia Drugs Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-23B8232
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Neutropenia Drugs Market Insights and Forecast to 2028
BUY CHAPTERS

Global Neutropenia Drugs Market Research Report 2025

Code: QYRE-Auto-23B8232
Report
January 2025
Pages:86
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Neutropenia Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Neutropenia Drugs Market

Neutropenia Drugs Market

The global market for Neutropenia Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Neutropenia Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neutropenia Drugs.
The Neutropenia Drugs market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neutropenia Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neutropenia Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Neutropenia Drugs Market Report

Report Metric Details
Report Name Neutropenia Drugs Market
CAGR 5%
Segment by Type
  • Capsule
  • Injection
Segment by Application
  • Hospital
  • Clinic
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Apotex Inc., Biogenomics Limited, Cellerant Therapeutics, Inc., Coherus BioSciences, Inc., Dr. Reddy’s Laboratories Limited, Ligand Pharmaceuticals, Inc., NAL Pharmaceuticals Ltd., Prolong Pharmaceuticals, LLC, Richter Gedeon Nyrt., Sandoz International GmbH
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Neutropenia Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Neutropenia Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Neutropenia Drugs Market report?

Ans: The main players in the Neutropenia Drugs Market are Apotex Inc., Biogenomics Limited, Cellerant Therapeutics, Inc., Coherus BioSciences, Inc., Dr. Reddy’s Laboratories Limited, Ligand Pharmaceuticals, Inc., NAL Pharmaceuticals Ltd., Prolong Pharmaceuticals, LLC, Richter Gedeon Nyrt., Sandoz International GmbH

What are the Application segmentation covered in the Neutropenia Drugs Market report?

Ans: The Applications covered in the Neutropenia Drugs Market report are Hospital, Clinic

What are the Type segmentation covered in the Neutropenia Drugs Market report?

Ans: The Types covered in the Neutropenia Drugs Market report are Capsule, Injection

Recommended Reports

Oncology Drugs

Hematology & Rare Diseases

Diagnostics & Therapeutics

1 Neutropenia Drugs Market Overview
1.1 Product Definition
1.2 Neutropenia Drugs by Type
1.2.1 Global Neutropenia Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Capsule
1.2.3 Injection
1.3 Neutropenia Drugs by Application
1.3.1 Global Neutropenia Drugs Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Neutropenia Drugs Market Size Estimates and Forecasts
1.4.1 Global Neutropenia Drugs Revenue 2020-2031
1.4.2 Global Neutropenia Drugs Sales 2020-2031
1.4.3 Global Neutropenia Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Neutropenia Drugs Market Competition by Manufacturers
2.1 Global Neutropenia Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Neutropenia Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Neutropenia Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Neutropenia Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Neutropenia Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Neutropenia Drugs, Product Type & Application
2.7 Global Key Manufacturers of Neutropenia Drugs, Date of Enter into This Industry
2.8 Global Neutropenia Drugs Market Competitive Situation and Trends
2.8.1 Global Neutropenia Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Neutropenia Drugs Players Market Share by Revenue
2.8.3 Global Neutropenia Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Neutropenia Drugs Market Scenario by Region
3.1 Global Neutropenia Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Neutropenia Drugs Sales by Region: 2020-2031
3.2.1 Global Neutropenia Drugs Sales by Region: 2020-2025
3.2.2 Global Neutropenia Drugs Sales by Region: 2026-2031
3.3 Global Neutropenia Drugs Revenue by Region: 2020-2031
3.3.1 Global Neutropenia Drugs Revenue by Region: 2020-2025
3.3.2 Global Neutropenia Drugs Revenue by Region: 2026-2031
3.4 North America Neutropenia Drugs Market Facts & Figures by Country
3.4.1 North America Neutropenia Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Neutropenia Drugs Sales by Country (2020-2031)
3.4.3 North America Neutropenia Drugs Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Neutropenia Drugs Market Facts & Figures by Country
3.5.1 Europe Neutropenia Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Neutropenia Drugs Sales by Country (2020-2031)
3.5.3 Europe Neutropenia Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neutropenia Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Neutropenia Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Neutropenia Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Neutropenia Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Neutropenia Drugs Market Facts & Figures by Country
3.7.1 Latin America Neutropenia Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Neutropenia Drugs Sales by Country (2020-2031)
3.7.3 Latin America Neutropenia Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Neutropenia Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Neutropenia Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Neutropenia Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Neutropenia Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Neutropenia Drugs Sales by Type (2020-2031)
4.1.1 Global Neutropenia Drugs Sales by Type (2020-2025)
4.1.2 Global Neutropenia Drugs Sales by Type (2026-2031)
4.1.3 Global Neutropenia Drugs Sales Market Share by Type (2020-2031)
4.2 Global Neutropenia Drugs Revenue by Type (2020-2031)
4.2.1 Global Neutropenia Drugs Revenue by Type (2020-2025)
4.2.2 Global Neutropenia Drugs Revenue by Type (2026-2031)
4.2.3 Global Neutropenia Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Neutropenia Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Neutropenia Drugs Sales by Application (2020-2031)
5.1.1 Global Neutropenia Drugs Sales by Application (2020-2025)
5.1.2 Global Neutropenia Drugs Sales by Application (2026-2031)
5.1.3 Global Neutropenia Drugs Sales Market Share by Application (2020-2031)
5.2 Global Neutropenia Drugs Revenue by Application (2020-2031)
5.2.1 Global Neutropenia Drugs Revenue by Application (2020-2025)
5.2.2 Global Neutropenia Drugs Revenue by Application (2026-2031)
5.2.3 Global Neutropenia Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Neutropenia Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Apotex Inc.
6.1.1 Apotex Inc. Company Information
6.1.2 Apotex Inc. Description and Business Overview
6.1.3 Apotex Inc. Neutropenia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Apotex Inc. Neutropenia Drugs Product Portfolio
6.1.5 Apotex Inc. Recent Developments/Updates
6.2 Biogenomics Limited
6.2.1 Biogenomics Limited Company Information
6.2.2 Biogenomics Limited Description and Business Overview
6.2.3 Biogenomics Limited Neutropenia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Biogenomics Limited Neutropenia Drugs Product Portfolio
6.2.5 Biogenomics Limited Recent Developments/Updates
6.3 Cellerant Therapeutics, Inc.
6.3.1 Cellerant Therapeutics, Inc. Company Information
6.3.2 Cellerant Therapeutics, Inc. Description and Business Overview
6.3.3 Cellerant Therapeutics, Inc. Neutropenia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Cellerant Therapeutics, Inc. Neutropenia Drugs Product Portfolio
6.3.5 Cellerant Therapeutics, Inc. Recent Developments/Updates
6.4 Coherus BioSciences, Inc.
6.4.1 Coherus BioSciences, Inc. Company Information
6.4.2 Coherus BioSciences, Inc. Description and Business Overview
6.4.3 Coherus BioSciences, Inc. Neutropenia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Coherus BioSciences, Inc. Neutropenia Drugs Product Portfolio
6.4.5 Coherus BioSciences, Inc. Recent Developments/Updates
6.5 Dr. Reddy’s Laboratories Limited
6.5.1 Dr. Reddy’s Laboratories Limited Company Information
6.5.2 Dr. Reddy’s Laboratories Limited Description and Business Overview
6.5.3 Dr. Reddy’s Laboratories Limited Neutropenia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Dr. Reddy’s Laboratories Limited Neutropenia Drugs Product Portfolio
6.5.5 Dr. Reddy’s Laboratories Limited Recent Developments/Updates
6.6 Ligand Pharmaceuticals, Inc.
6.6.1 Ligand Pharmaceuticals, Inc. Company Information
6.6.2 Ligand Pharmaceuticals, Inc. Description and Business Overview
6.6.3 Ligand Pharmaceuticals, Inc. Neutropenia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Ligand Pharmaceuticals, Inc. Neutropenia Drugs Product Portfolio
6.6.5 Ligand Pharmaceuticals, Inc. Recent Developments/Updates
6.7 NAL Pharmaceuticals Ltd.
6.7.1 NAL Pharmaceuticals Ltd. Company Information
6.7.2 NAL Pharmaceuticals Ltd. Description and Business Overview
6.7.3 NAL Pharmaceuticals Ltd. Neutropenia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 NAL Pharmaceuticals Ltd. Neutropenia Drugs Product Portfolio
6.7.5 NAL Pharmaceuticals Ltd. Recent Developments/Updates
6.8 Prolong Pharmaceuticals, LLC
6.8.1 Prolong Pharmaceuticals, LLC Company Information
6.8.2 Prolong Pharmaceuticals, LLC Description and Business Overview
6.8.3 Prolong Pharmaceuticals, LLC Neutropenia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Prolong Pharmaceuticals, LLC Neutropenia Drugs Product Portfolio
6.8.5 Prolong Pharmaceuticals, LLC Recent Developments/Updates
6.9 Richter Gedeon Nyrt.
6.9.1 Richter Gedeon Nyrt. Company Information
6.9.2 Richter Gedeon Nyrt. Description and Business Overview
6.9.3 Richter Gedeon Nyrt. Neutropenia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Richter Gedeon Nyrt. Neutropenia Drugs Product Portfolio
6.9.5 Richter Gedeon Nyrt. Recent Developments/Updates
6.10 Sandoz International GmbH
6.10.1 Sandoz International GmbH Company Information
6.10.2 Sandoz International GmbH Description and Business Overview
6.10.3 Sandoz International GmbH Neutropenia Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Sandoz International GmbH Neutropenia Drugs Product Portfolio
6.10.5 Sandoz International GmbH Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neutropenia Drugs Industry Chain Analysis
7.2 Neutropenia Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neutropenia Drugs Production Mode & Process Analysis
7.4 Neutropenia Drugs Sales and Marketing
7.4.1 Neutropenia Drugs Sales Channels
7.4.2 Neutropenia Drugs Distributors
7.5 Neutropenia Drugs Customer Analysis
8 Neutropenia Drugs Market Dynamics
8.1 Neutropenia Drugs Industry Trends
8.2 Neutropenia Drugs Market Drivers
8.3 Neutropenia Drugs Market Challenges
8.4 Neutropenia Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Neutropenia Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Neutropenia Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Neutropenia Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Neutropenia Drugs Sales (MT) of Key Manufacturers (2020-2025)
 Table 5. Global Neutropenia Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Neutropenia Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Neutropenia Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Neutropenia Drugs Average Price (USD/MT) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Neutropenia Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Neutropenia Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Neutropenia Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Neutropenia Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Neutropenia Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neutropenia Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Neutropenia Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Neutropenia Drugs Sales by Region (2020-2025) & (MT)
 Table 18. Global Neutropenia Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Neutropenia Drugs Sales by Region (2026-2031) & (MT)
 Table 20. Global Neutropenia Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Neutropenia Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Neutropenia Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Neutropenia Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Neutropenia Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Neutropenia Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Neutropenia Drugs Sales by Country (2020-2025) & (MT)
 Table 27. North America Neutropenia Drugs Sales by Country (2026-2031) & (MT)
 Table 28. North America Neutropenia Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Neutropenia Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Neutropenia Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Neutropenia Drugs Sales by Country (2020-2025) & (MT)
 Table 32. Europe Neutropenia Drugs Sales by Country (2026-2031) & (MT)
 Table 33. Europe Neutropenia Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Neutropenia Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Neutropenia Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Neutropenia Drugs Sales by Region (2020-2025) & (MT)
 Table 37. Asia Pacific Neutropenia Drugs Sales by Region (2026-2031) & (MT)
 Table 38. Asia Pacific Neutropenia Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Neutropenia Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Neutropenia Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Neutropenia Drugs Sales by Country (2020-2025) & (MT)
 Table 42. Latin America Neutropenia Drugs Sales by Country (2026-2031) & (MT)
 Table 43. Latin America Neutropenia Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Neutropenia Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Neutropenia Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Neutropenia Drugs Sales by Country (2020-2025) & (MT)
 Table 47. Middle East and Africa Neutropenia Drugs Sales by Country (2026-2031) & (MT)
 Table 48. Middle East and Africa Neutropenia Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Neutropenia Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Neutropenia Drugs Sales (MT) by Type (2020-2025)
 Table 51. Global Neutropenia Drugs Sales (MT) by Type (2026-2031)
 Table 52. Global Neutropenia Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Neutropenia Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Neutropenia Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Neutropenia Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Neutropenia Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Neutropenia Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Neutropenia Drugs Price (USD/MT) by Type (2020-2025)
 Table 59. Global Neutropenia Drugs Price (USD/MT) by Type (2026-2031)
 Table 60. Global Neutropenia Drugs Sales (MT) by Application (2020-2025)
 Table 61. Global Neutropenia Drugs Sales (MT) by Application (2026-2031)
 Table 62. Global Neutropenia Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Neutropenia Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Neutropenia Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Neutropenia Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Neutropenia Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Neutropenia Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Neutropenia Drugs Price (USD/MT) by Application (2020-2025)
 Table 69. Global Neutropenia Drugs Price (USD/MT) by Application (2026-2031)
 Table 70. Apotex Inc. Company Information
 Table 71. Apotex Inc. Description and Business Overview
 Table 72. Apotex Inc. Neutropenia Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
 Table 73. Apotex Inc. Neutropenia Drugs Product
 Table 74. Apotex Inc. Recent Developments/Updates
 Table 75. Biogenomics Limited Company Information
 Table 76. Biogenomics Limited Description and Business Overview
 Table 77. Biogenomics Limited Neutropenia Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
 Table 78. Biogenomics Limited Neutropenia Drugs Product
 Table 79. Biogenomics Limited Recent Developments/Updates
 Table 80. Cellerant Therapeutics, Inc. Company Information
 Table 81. Cellerant Therapeutics, Inc. Description and Business Overview
 Table 82. Cellerant Therapeutics, Inc. Neutropenia Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
 Table 83. Cellerant Therapeutics, Inc. Neutropenia Drugs Product
 Table 84. Cellerant Therapeutics, Inc. Recent Developments/Updates
 Table 85. Coherus BioSciences, Inc. Company Information
 Table 86. Coherus BioSciences, Inc. Description and Business Overview
 Table 87. Coherus BioSciences, Inc. Neutropenia Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
 Table 88. Coherus BioSciences, Inc. Neutropenia Drugs Product
 Table 89. Coherus BioSciences, Inc. Recent Developments/Updates
 Table 90. Dr. Reddy’s Laboratories Limited Company Information
 Table 91. Dr. Reddy’s Laboratories Limited Description and Business Overview
 Table 92. Dr. Reddy’s Laboratories Limited Neutropenia Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
 Table 93. Dr. Reddy’s Laboratories Limited Neutropenia Drugs Product
 Table 94. Dr. Reddy’s Laboratories Limited Recent Developments/Updates
 Table 95. Ligand Pharmaceuticals, Inc. Company Information
 Table 96. Ligand Pharmaceuticals, Inc. Description and Business Overview
 Table 97. Ligand Pharmaceuticals, Inc. Neutropenia Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
 Table 98. Ligand Pharmaceuticals, Inc. Neutropenia Drugs Product
 Table 99. Ligand Pharmaceuticals, Inc. Recent Developments/Updates
 Table 100. NAL Pharmaceuticals Ltd. Company Information
 Table 101. NAL Pharmaceuticals Ltd. Description and Business Overview
 Table 102. NAL Pharmaceuticals Ltd. Neutropenia Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
 Table 103. NAL Pharmaceuticals Ltd. Neutropenia Drugs Product
 Table 104. NAL Pharmaceuticals Ltd. Recent Developments/Updates
 Table 105. Prolong Pharmaceuticals, LLC Company Information
 Table 106. Prolong Pharmaceuticals, LLC Description and Business Overview
 Table 107. Prolong Pharmaceuticals, LLC Neutropenia Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
 Table 108. Prolong Pharmaceuticals, LLC Neutropenia Drugs Product
 Table 109. Prolong Pharmaceuticals, LLC Recent Developments/Updates
 Table 110. Richter Gedeon Nyrt. Company Information
 Table 111. Richter Gedeon Nyrt. Description and Business Overview
 Table 112. Richter Gedeon Nyrt. Neutropenia Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
 Table 113. Richter Gedeon Nyrt. Neutropenia Drugs Product
 Table 114. Richter Gedeon Nyrt. Recent Developments/Updates
 Table 115. Sandoz International GmbH Company Information
 Table 116. Sandoz International GmbH Description and Business Overview
 Table 117. Sandoz International GmbH Neutropenia Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2020-2025)
 Table 118. Sandoz International GmbH Neutropenia Drugs Product
 Table 119. Sandoz International GmbH Recent Developments/Updates
 Table 120. Key Raw Materials Lists
 Table 121. Raw Materials Key Suppliers Lists
 Table 122. Neutropenia Drugs Distributors List
 Table 123. Neutropenia Drugs Customers List
 Table 124. Neutropenia Drugs Market Trends
 Table 125. Neutropenia Drugs Market Drivers
 Table 126. Neutropenia Drugs Market Challenges
 Table 127. Neutropenia Drugs Market Restraints
 Table 128. Research Programs/Design for This Report
 Table 129. Key Data Information from Secondary Sources
 Table 130. Key Data Information from Primary Sources
 Table 131. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Neutropenia Drugs
 Figure 2. Global Neutropenia Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Neutropenia Drugs Market Share by Type: 2024 & 2031
 Figure 4. Capsule Product Picture
 Figure 5. Injection Product Picture
 Figure 6. Global Neutropenia Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Neutropenia Drugs Market Share by Application: 2024 & 2031
 Figure 8. Hospital
 Figure 9. Clinic
 Figure 10. Global Neutropenia Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Neutropenia Drugs Market Size (2020-2031) & (US$ Million)
 Figure 12. Global Neutropenia Drugs Sales (2020-2031) & (MT)
 Figure 13. Global Neutropenia Drugs Average Price (USD/MT) & (2020-2031)
 Figure 14. Neutropenia Drugs Report Years Considered
 Figure 15. Neutropenia Drugs Sales Share by Manufacturers in 2024
 Figure 16. Global Neutropenia Drugs Revenue Share by Manufacturers in 2024
 Figure 17. Global 5 and 10 Largest Neutropenia Drugs Players: Market Share by Revenue in Neutropenia Drugs in 2024
 Figure 18. Neutropenia Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 19. Global Neutropenia Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 20. North America Neutropenia Drugs Sales Market Share by Country (2020-2031)
 Figure 21. North America Neutropenia Drugs Revenue Market Share by Country (2020-2031)
 Figure 22. U.S. Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 23. Canada Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Europe Neutropenia Drugs Sales Market Share by Country (2020-2031)
 Figure 25. Europe Neutropenia Drugs Revenue Market Share by Country (2020-2031)
 Figure 26. Germany Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. France Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. U.K. Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Italy Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Russia Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Asia Pacific Neutropenia Drugs Sales Market Share by Region (2020-2031)
 Figure 32. Asia Pacific Neutropenia Drugs Revenue Market Share by Region (2020-2031)
 Figure 33. China Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Japan Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. South Korea Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. India Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Australia Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Taiwan Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Indonesia Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Thailand Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Malaysia Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Philippines Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Neutropenia Drugs Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Neutropenia Drugs Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Neutropenia Drugs Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Neutropenia Drugs Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. U.A.E Neutropenia Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Neutropenia Drugs by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Neutropenia Drugs by Type (2020-2031)
 Figure 55. Global Neutropenia Drugs Price (USD/MT) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Neutropenia Drugs by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Neutropenia Drugs by Application (2020-2031)
 Figure 58. Global Neutropenia Drugs Price (USD/MT) by Application (2020-2031)
 Figure 59. Neutropenia Drugs Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Lukasiewicz Research Network